Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer must be confirmed by biopsy.
- Your cancer must have spread to bones, lymph nodes, or both, but not to organs like the liver or lungs.
- You must have already had at least two prior chemotherapy regimens (taxane-based), or if you had only one, a second one must not be available or suitable for you.
- You must have been treated with a PSMA-targeted therapy (e.g., lutetium Lu-177 vipivotide tetraxetan), or that treatment must be unavailable, not accessible, or not suitable for you.
- If you have a BRCA gene mutation, you must have been treated with a PARP inhibitor, or that treatment must be unavailable, not accessible, or not suitable.
- You must meet certain blood test and organ function requirements (e.g., adequate kidney and liver function, blood cell counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Hear when a new Metastatic Castration-resistant Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.